ChartMill assigns a Buy % Consensus number of 46% to ASXC. The Buy consensus is the weighted average rating of the current analysts ratings.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-05-16 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2024-04-04 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-03-22 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-16 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2023-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-08-22 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-03-06 | HC Wainwright & Co. | Maintains | Buy |
| 2023-02-22 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-01-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-09-08 | Cantor Fitzgerald | Initiate | Overweight |
| 2022-08-10 | HC Wainwright & Co. | Maintains | Buy |
| 2021-05-26 | HC Wainwright & Co. | Initiate | Buy |
7 analysts have analysed ASXC and the average price target is 0.36 USD. This implies a price increase of 2.62% is expected in the next year compared to the current price of 0.3479.
The consensus rating for Asensus Surgical Inc (ASXC) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.